Research Paper on:
EDTA Chelation Therapy as an Alternative Treatment Approach

Unformatted Sample Text from the Research Paper:
been used - and accepted - for decades. An outgrowth of that approach to detoxification has been the use of intravenous ethylenediaminetetraacetate (EDTA) for the treatment of atherosclerosis.  The practice has been researched for decades as well, and it is gaining growing acceptance as an alternative treatment for arterial disease. It does not meet the criteria that  the medical community has established for mainstream medical practice, however. The American Medical Association (AMA) consistently denounces EDTA chelation therapy as being little more than hocus-pocus; most MDs familiar  with the term with it refuse to discuss it at all. Proponents of the therapy claim that it is the political machine of  medicine that prevents EDTA chelation therapy from becoming the first treatment of choice for arterial disease. As the therapy comes to be more widely used, practitioners have noticed other  benefits. Some patients have experienced increased blood flow to the brain, others have been able to avoid amputation. EDTA chelation therapy appears to provide a means by which  Medicare could greatly reduce its payments to care providers. What EDTA Chelation Therapy Is This is not a quick-fix solution to conditions that  have taken years to develop. The most vocal proponent of the treatment, Elmer M. Cranton, M.D., maintains that the only effective method of gaining positive results is through the  use of intravenous delivery of EDTA over a three-hour period. The intravenous delivery typically occurs two or three times a week for the first several weeks before reducing frequency  to once or twice a week. A full course of treatment generally is considered to consist of 30 IV infusions costing about $115 each.